Skip to main content
Print Save

Alecensa FDA Approval History

FDA Approved: Yes (First approved December 11, 2015)
Brand name: Alecensa
Generic name: alectinib
Dosage form: Capsules
Company: Genentech, Inc.
Treatment for: Non-Small Cell Lung Cancer

Alecensa (alectinib) is an oral, anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive non-small cell lung cancer (NSCLC).

Development timeline for Alecensa

DateArticle
Jun 12, 2023Food-Drug Interactions Could be Impactful for Some Lung Cancer Patients
Nov  6, 2017Approval FDA Approves Alecensa (alectinib) as First-Line Treatment for ALK-Positive Metastatic Non-Small Cell Lung Cancer
Jun  5, 2017Phase III Study Showed Genentech’s Alecensa (Alectinib) Reduced the Risk of Disease Progression or Death by More Than Half Versus Crizotinib as First-Line Treatment in a Specific Type of Lung Cancer
Dec 11, 2015Approval FDA Approves Alecensa (alectinib) for ALK-Positive Non-Small Cell Lung Cancer
Sep  8, 2015FDA Grants Genentech's Alectinib Priority Review for Specific Type of ALK-Positive Lung Cancer

See also

Alecensa (alectinib) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer